Overview
Major clinical trials presented at oncology conferences often influence the standard of care for cancer treatment. However, a gap exists in our understanding of how these trial results are discussed and adopted in real-world practice.
Researchers used artificial intelligence (AI) to analyze electronic health records of over 8,650 patients for real-world patient discussions documented by clinicians about landmark clinical trials presented as part of the ASCO Plenary Symposium between 2021-2025. The study examined drivers for the trial discussion, the clinician's perspective on the trial, whether patients actually started the recommended treatment, and reasons why not. The researcher then reviewed these findings to ensure accuracy and identify common themes.
Most clinicians were optimistic about trial treatments (47-93% had positive sentiment). Yet only 64% of patients actually started the recommended trial therapy. The main reasons patients didn't receive trial treatments included clinical factors (not meeting eligibility criteria, having medical conditions), systemic barriers (insurance coverage, transportation), and patient preferences (wanting to maintain quality of life or avoid side effects).
Why this matters
This is the largest analysis of real-world clinician-patient trial discussions to date. It reveals that the gap between clinical evidence and real-world practice isn't about skeptical doctors but frequently the practical and personal factors that make treatments unsuitable for individual patients. These insights can help healthcare systems identify and remove barriers to ensuring all eligible patients benefit from the latest evidence-based treatments.